Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis Report By Type (C-reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Pre-albumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, Free Light Chain Diagnostic Test, Others), By Application (Autoimmune Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, Toxicology Testing, Others), By Technology (Radioimmunoassay, Immunoturbidity Assay, Immunoprotein Electrophoresis, Enzyme-linked immunosorbent assay) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global immunoprotein diagnostic testing market size was valued at USD 11544.62 million in 2021, and it is anticipated to reach USD 19424.34 million by 2030 at a CAGR of 6.72%.

The term "immunoproteins" refers to the proteins found in the blood that are active participants in the process of the immune system's operation. These proteins exhibit an abnormal increase in blood concentration, which enables them to function as a potential indicator in disease diagnosis when the body is in an unhealthy state. Since they are immunologically active against pathogenic organisms and substances, they can aid in disease diagnosis.

Immunoproteins can be found in cells, tissues, or organs, and they work together to build an integrated biological system that can mitigate the potentially damaging effects of antigens. Infectious disorders, cardiovascular diseases, and oncological conditions can all be more accurately diagnosed thanks to the immunoproteins' contribution.

Market Dynamics

Driving Factors

The high frequency of chronic diseases is expected to drive increased global market sales

The rise in chronic disease prevalence and incidence rate is the primary factor driving the need for immunoprotein diagnostic testing services. According to the World Health Organization (WHO), the Global Health Observatory (GHO) data suggests that diabetes is responsible for approximately 1.6 million fatalities annually, accounting for approximately 2.8% of all deaths. In addition, the numbers presented in the WHO report indicate that lung cancer was responsible for almost 1.6 million fatalities worldwide in 2012. Early diagnosis and appropriate diagnostic testing are required to reduce the mortality rates caused by chronic conditions. That is where global immunoprotein diagnostic testing has the potential to serve a large population, thereby fueling its expansion on a global scale.

The growing elderly population and the high prevalence of non-communicable diseases drive the global market

The global market for immunoprotein diagnostic testing is driven primarily by the rising prevalence and incidence of chronic diseases among the world's ageing population. Diabetic populations have increased dramatically since 1980 when the WHO recorded 108 million cases. By 2014, that figure had grown to 422 million (WHO).

Additionally, according to data from the WHO's Global Health Observatory, non-communicable diseases (NCDs), including cancer, diabetes, chronic lung diseases, and cardiovascular illnesses, account for up to 39.5 million deaths globally in 2017.

Additional market drivers for immunoprotein diagnostic testing include public awareness of early diagnosis, well-developed healthcare systems, and increased infectious illness incidence in developing nations due to filthy living circumstances. The market expansion, however, is being slowed down by the short product shelf lives and low per capita income in various nations.

Market Opportunities

Increasing awareness among patients and developments in diagnostic tests will create growth opportunities for the market

The market for immunoprotein diagnostic testing is expected to increase significantly as people become more aware of its benefits.

Despite this, the immunoprotein diagnostic testing market is expected to rise throughout the forecast period due to advances in condition-specific assays and tests and technological advancements.

Restraining Factors

Unfavorable reimbursement situation

Insufficient funding for infectious disease diagnostics significantly hinders the sector's expansion. Getting health insurance companies to pay for diagnostic testing is one of the most significant obstacles that most entrepreneurs must overcome to commercialize their products successfully.

Regional Analysis

The global market for immunoprotein diagnostic testing is divided into North America, Europe, Asia-Pacific, and LAMEA based on region.

Due to an increasing number of elderly people and an increasing disease burden, North America is expected to become the most powerful region. The Institute of Health Metrics and Evaluation discovered that the DALYS was approximately 24,305 in 2017, and their findings can be seen here. Fifty-two million Americans were at least 65 years old in 2018, according to the United States Census Bureau's 2018 data. As a result of a slower metabolism and a less robust immune system, the elderly population is at increased risk for developing chronic diseases and is more likely to be affected by these conditions. NIDDK conducted a study in 2018 that indicated that one-quarter of the elderly population suffers from diabetes, which is likely to climb over the next few decades, according to the findings. Because of this, early disease detection is essential to ensure that patients receive the appropriate care. Consequently, it is anticipated that it will have a favorable influence on the market for immunoprotein diagnostic testing.

Segmental Analysis

The global market for immunoprotein diagnostic testing is divided into four parts based on product type, technology, application and region. The Immunoglobulin Diagnostic Test, Pre-albumin Diagnostic Test, C-reactive Protein Diagnostic Test,  Haptoglobin Diagnostic Test, Free Light Chain Diagnostic Test, Complement System Protein Diagnostic Test, and Others segments are further broken down based on type. Due to the rising prevalence of autoimmune illnesses globally, the immunoglobulin diagnostic testing segment contributed the most to revenue.

According to application, the market is divided into Autoimmune Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, Toxicology Testing and Others. Due to the increasing prevalence of infectious disorders such as HIV-1, HIV-1/2, hepatitis B, hepatitis C, and human T-lymphotropic virus types I & II, the infectious disease testing segment was the most significant revenue contributor.

According to technique, the market is split into Immunoturbidity Assay, Radioimmunoassay, Enzyme-Linked Immunosorbent Assay, Immunoprotein Electrophoresis, and Others. Further, the Enzyme-linked immunosorbent assay is sub-segmented into Chemiluminescence Immunoassay, Fluorescence Immunoassay and Colorimetric immunoassay. The enzyme-based immunoassay segment was the largest contributor to the global market. It was linked to the increasing use of immunoassays in cancer, POC IVD testing, infectious illness testing, therapeutic drug level monitoring, and the development of novel biomarkers. The advantages of ELISA include a long shelf life and ease of use, which has led to the growing acceptance of these tests in the academic and industrial sectors.

Impact of covid-19

COVID-19 has positive and negative market consequences, as carbon emissions have decreased globally due to the lockout. COVID-19's reduction in emissions is a short-term benefit. Still, when industries and enterprises attempt to recoup some of their financial losses in the first quarter of the year, carbon emissions will rise dramatically. COVID-19 had a negative impact on global recycling efforts. Countries, notably the United States, have halted or decreased recycling programs to focus on collecting additional domestic waste or because services have been disrupted by the virus.

Also, with industries slowly returning to normalcy following the COVID-19 outbreak, this shift in workplace health and safety is expected to increase due to mandatory social distancing and continuous personal care through sanitization to eliminate even the tiniest possibility of COVID-19 spread. COVID-19 has impacted various companies' revenues, and if the lockdown is lifted, companies will turn their attention to operations to make up for their losses.

Recent Developments